Melperone in the treatment of iatrogenic psychosis in Parkinson's disease

Functional Neurology

Volumn 11, Issue 4, 1996, Pages 201-207

  Barbato, Luca ^a   Monge, Alessandra ^a   Stocchi, Fabrizio ^a,b   Nordera, Giampietro ^a  

^a Istituto Antonio Benedetti   (Italy)

^b Ist Mediterraneo Neurosci Sanatrix   (Italy)

Author keywords

Iatrogenic psychosis; Melperone; Neuroleptic drugs; Parkinson's disease

Indexed keywords

ANTIPARKINSON AGENT; LEVODOPA; MELPERONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HYPOTENSION; MALE; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PSYCHOSIS; VERTIGO;

AGED; ANTIPARKINSON AGENTS; ANTIPSYCHOTIC AGENTS; BUTYROPHENONES; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; PSYCHOSES, SUBSTANCE-INDUCED; TREATMENT OUTCOME;

EID: 0029854923     PISSN: 03935264     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Fonda D. Parkinson's disease in the elderly: psychiatric manifestations. Geriatrics 1985;40:109-114
2. Mayeux R, Stern Y, Rosen J et al. Depression, intellectual impairment and Parkinson' disease. Neurology 1980;31:645-650
3. Damasio AR, Lobo Antunes J, Macedo C. Psychiatric aspects in parkinsonism treated with L-dopa. J Neurol Neurosurg Psychiatry 1971;34:502-507
4. Celesia GG, Barr AN. Psychosis and other psychiatric manifestations of levodopa therapy. Arch Neurol 1970;23:193-200
5. Fhan S. Adverse effects of levodopa. In: Olanow CW, Lieberman AN, eds The scientific basis of the treament of Parkinson's disease. New Jersey; Parthenon Publishing Group 1992:89-112
6. Banerjee AK, Falkai PG, Savidge M. Visual hallucinations in the elderly associated with the use of levodopa. Postgrad Med J 1983;65:358-361
7. Goetz CG, Tanner CM, Klawans HL. Pharmacology of hallucinations induced by long-term drug therapy. Am J Psychiatry 1982;139:494-497
8. Klawans HL. Psychiatric side effects during treatment of Parkinson's disease. J Neurological Transmission 1988;27:117-122
9. Melamed E. Hallucinosis in patients with advanced Parkinson's disease: clinical features, biochemical mechanism and therapeutic strategies. In: Battistin L, Ruggieri S eds Patologia extrapiramidale degenerativa e iatrogena. Roma; Edizioni Don Guanella 1993:331-336
10. Nausieda PA, Tanner CM, Klawans HL. Serotonergically active agents in levodopa-induced psychiatric toxicity reactions. Adv Neurol 1983;37:23-32
11. Friedman JH. The management of levodopa psychosis. Clin Neuropharmacol 1991; 14:283-295
12. Stockmeier CA, Di Carlo J, Zhang Y, Thompson P, Meltzer HY. Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin and dopamine receptors. J Pharmacol Exp Ther 1993;266:1374-1384
13. Christensson EG. Pharmacological data of the atypical neuroleptic compound melperone (Buronil®). Acta Psychiatr Scand 1989; 352:7-15
14. 3H Cis-(Z)-fluphentixol binding and on adenylate cyclase activity in vitro. Life Sci 1978;23:551-556
15. Holstein MF, Folstein SE, McHugh PR. "Mini-mental Status". A pratical method for grading the cognitive state of patients for the physician. J Psychiatr Res 1975;12: 189-198
16. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-442
17. Fhan S, Elton RL and members of UPDRS Development Committee. Unified Parkinson's disease rating scale. In: Fhan S, Marsden CD, Calne D, Goldstein M eds Recent developments in Parkinson's disease. Florham Park, New Jersey; MacMillan Healthcare Information 1987:11:427-442
18. Overall J, Gorham D. Brief psychiatric rating scale. Psychol Rep 1962;10:799-818